BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251030T190000
DTEND;TZID=Africa/Nairobi:20251030T203000
DTSTAMP:20260525T220802
CREATED:20251029T090350Z
LAST-MODIFIED:20251223T153247Z
UID:40485-1761850800-1761856200@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Hepatocellular Carcinoma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nMultidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited) \nDate: 30th October 2025Time: 7:00 PM – 8:30 PM EAT \nModerator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon\, Hercules Healthcare \nSpeakers: \n\nDr. Gladwell KiarieMedical Oncologist\, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends\nDr. Eric MurungaConsultant Physician\, Gastroenterologist; Chairman\, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings\nDr. Samuel NgukuConsultant\, Radiology and Nuclear Medicine\, Aga Khan University Hospital\, NairobiTopic: Imaging of Hepatocellular Carcinoma\n\nOrganized by:Kenya Society of Haematology & Oncology (KESHO) \nPartner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nThe Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates \nPresentations by Dr Gladwell Kiarie and Dr Eric Murunga \nTwo complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC)\, with a focus on pragmatic\, evidence-based approaches applicable to resource-limited settings. \nDr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma\, emphasizing the importance of stage-guided\, individualized care. Using established staging frameworks\, she highlighted how tumor burden\, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies\, including immunotherapy and targeted agents\, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making\, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC. \nDr Eric Murunga addressed the management of chronic Hepatitis B within real-world\, resource-constrained contexts. He outlined practical diagnostic pathways\, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools\, long-term antiviral therapy and structured follow-up. Preventive strategies including screening\, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer. \nTogether\, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease\, particularly viral hepatitis. \nKey takeaway: Strengthening early identification and treatment of chronic Hepatitis B\, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma\, is central to reducing advanced liver cancer and improving survival in resource-limited settings.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-hepatocellular-carcinoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-28-at-2.53.20-PM-e1761728953517.jpeg
END:VEVENT
END:VCALENDAR